 After 9 months of ADT, all patients are assessed for response. Patients with PSA 4 ngmL may discontinue ADT. These patients are followed every 3 months. Treatment may be restarted when PSA is 20 ngmL OR PSA is the PSA level at study entry OR at clinical progression. 